A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

NCT05704738 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

532

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: Rocatinlimab
DRUG: Placebo

Sponsor

Amgen